introduction radiation exposures from diagnostic medical examinations are generally low and are almost always justified by the benefits of accurate diagnosis of possible disease conditions. therefore, entrance skin dose (esd), body organ dose (bod), and effective dose (ed) from adult patients undergoing routine thorax posterior-anterior (pa) and thorax right lateral (rlat) were estimated in uni...

background: changes in body composition may be used for monitoring progression/ regression of a disease. prompt γ-rays in vivo neutron activation analysis (ivnaa) has been widely used for the measurement of body composition in recent years. objective: in this paper, we tried to improve the safety of ivnaa operator. methods: the most important factor for reducing the operator receiving dose is t...

introduction: nowadays,  considerable developments  in  the field  of  radiotherapy have  been  achieved.  they  include  the  advances  made  in  the  equipments  and  treatment  planning  techniques  which  require  highly complex calculations. such achievements have made it possible to treat cancer patients not only  with  higher  radiation  dose  but  also  with  higher  precision  and  con...

BACKGROUND Preclinical studies have demonstrated that MIS416, a bacterially derived immune modulator, targets myeloid cells following systemic delivery. MIS416 stimulated myeloid cells have the capacity to regulate innate inflammation, a potential therapeutic target for progressive multiple sclerosis. OBJECTIVES To determine the safety, tolerability, pharmacodynamics and maximum tolerated dos...

The stability of delivery of low monitor unit (MU) setting is important especially for step-andshoot intensity-modulated radiotherapy (IMRT), because the nature of the technique is inherent to repeat beam on/off according to the number of the segments. This study evaluates the dose linearity and profile flatness/symmetry under low MU settings for Vero4DRT, a new linear-accelerator based irradia...

The safety profile of HibMenCY was compared with licensed Hib conjugate vaccines in a pooled analysis that included more than 8,500 subjects who were administered a four-dose series of HibMenCY or commercially available Hib vaccines at 2, 4, 6 and 12-15 mo of age in two primary vaccination and two fourth dose phase 3 studies. In all studies, HibMenCY or Hib vaccine was co-administered with age-...